Sevoflurane's Effect on Neurocognition Study

Launched by KEITH M VOGT · Sep 17, 2023

Keywords

ClinConnect Summary

The Sevoflurane's Effect on Neurocognition Study is designed to explore how acute pain affects long-term memory and physical responses, especially when using a low dose of an anesthetic called sevoflurane. Researchers will use a special imaging technique to see how the brain reacts under these conditions. The study involves two visits and does not require any long-term follow-up.

To participate, individuals must be between 18 and 59 years old, speak English, and have normal hearing and memory. They should be generally healthy, without significant chronic diseases. However, certain conditions would exclude someone from participating, such as being pregnant, having memory problems, or taking specific medications. Participants can expect to attend two visits where they will undergo assessments related to memory and brain function. This study is currently looking for volunteers, so if you meet the criteria and are interested, it could be a valuable opportunity to contribute to important research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults, age 18-59, who are native English speakers with at least a high school education
• • have normal hearing and memory
• • be of normal body-weight
• • be generally healthy (free from significant chronic disease)
• • have none of the specific exclusion criteria
• • have a valid email address and valid phone number throughout the study
• • anticipate ability to participate in all visits required for the phase of the study in which they are enrolled
• Exclusion Criteria:
• • being pregnant or attempting to conceive
• • having a body mass index (BMI) \> 35
• • having significant memory impairment or hearing loss
• • having sleep apnea
• • having chronic pain or frequently taking pain medication (including tramadol)
• • having any severe or poorly-controlled medical problem (hypertension, diabetes)
• • having neurologic or psychiatric disease, including anxiety, and depression
• • having significant cardiac valvular disease or cardiomyopathy
• • having a history of abnormal heartbeats (cardiac conduction abnormality or arrhythmia)
• • having a history of seizures or convulsions
• • having a history of liver disease
• • having a history of asthma or other significant pulmonary disease
• • having a history of malignant hyperthermia, muscular dystrophy, central core disease, or hyperkalemia
• • being claustrophobic
• • have metal implants or non-removable metal piercings
• • having a history of adverse reaction to anesthetics
• • daily alcohol or heavy alcohol use; history of alcohol abuse
• • current daily smoker
• • regular or recent marijuana use (including prescribed/medical marijuana)
• • illicit drug use
• • regularly taking: antiepileptics, antidepressants, anti-psychotics, antihistamines, anti-anxiety medication, stimulants, or sleep-aids
• • current use of selective serotonin reuptake inhibitors (SSRIs), noradrenaline reuptake inhibitors (SNRIs), or monoamine oxidase inhibitors (MAOIs) and some other specific drugs phenytoin, carbamazepine, and rifampin
• • history of QT prolongation
• • hypersensitivity or allergic reaction to ondansetron (Zofran)